1. Home
  2. GRBK vs RARE Comparison

GRBK vs RARE Comparison

Compare GRBK & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRBK
  • RARE
  • Stock Information
  • Founded
  • GRBK N/A
  • RARE 2010
  • Country
  • GRBK United States
  • RARE United States
  • Employees
  • GRBK N/A
  • RARE N/A
  • Industry
  • GRBK Homebuilding
  • RARE Biotechnology: Pharmaceutical Preparations
  • Sector
  • GRBK Consumer Discretionary
  • RARE Health Care
  • Exchange
  • GRBK Nasdaq
  • RARE Nasdaq
  • Market Cap
  • GRBK 3.1B
  • RARE 2.6B
  • IPO Year
  • GRBK N/A
  • RARE 2014
  • Fundamental
  • Price
  • GRBK $72.61
  • RARE $29.11
  • Analyst Decision
  • GRBK Buy
  • RARE Strong Buy
  • Analyst Count
  • GRBK 2
  • RARE 14
  • Target Price
  • GRBK $71.00
  • RARE $86.64
  • AVG Volume (30 Days)
  • GRBK 211.4K
  • RARE 1.4M
  • Earning Date
  • GRBK 10-29-2025
  • RARE 11-04-2025
  • Dividend Yield
  • GRBK N/A
  • RARE N/A
  • EPS Growth
  • GRBK 7.68
  • RARE N/A
  • EPS
  • GRBK 7.83
  • RARE N/A
  • Revenue
  • GRBK $2,137,742,000.00
  • RARE $610,159,000.00
  • Revenue This Year
  • GRBK N/A
  • RARE $19.72
  • Revenue Next Year
  • GRBK $6.60
  • RARE $23.29
  • P/E Ratio
  • GRBK $9.22
  • RARE N/A
  • Revenue Growth
  • GRBK 13.87
  • RARE 26.77
  • 52 Week Low
  • GRBK $50.57
  • RARE $25.81
  • 52 Week High
  • GRBK $84.66
  • RARE $59.90
  • Technical
  • Relative Strength Index (RSI)
  • GRBK 56.38
  • RARE 43.11
  • Support Level
  • GRBK $71.01
  • RARE $28.62
  • Resistance Level
  • GRBK $75.50
  • RARE $29.89
  • Average True Range (ATR)
  • GRBK 2.05
  • RARE 1.02
  • MACD
  • GRBK -0.20
  • RARE -0.26
  • Stochastic Oscillator
  • GRBK 59.92
  • RARE 12.37

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Share on Social Networks: